healthFDA Approves Cobenfy as First New Pharmacological Class for Schizophrenia in Three Decades
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride) for adult schizophrenia, introducing the first novel biological mechanism for the psychiatric disorder in more than 30 years.
